Next Article in Journal
Muscular VSD Device Complications: Literature Review and Possible Implications for Echocardiographic Follow-Up
Previous Article in Journal
Clinical Characteristics and Outcomes of 1894 Women with Peripartum Cardiomyopathy Treated with and Without Levosimendan in Germany
Previous Article in Special Issue
Genetic Architecture of Ischemic Stroke: Insights from Genome-Wide Association Studies and Beyond
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCDD
Volume 13
Issue 3
10.3390/jcdd13030127
jcdd-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Systematic Review

Genome-Wide Association Studies of Myocardial Infarction: A Systematic Literature Review

by
Isabelle P. Thierry
1,*,
Reza Jabbari
1,
Thomas Engstrøm
1,
Jacob Tfelt-Hansen
1,2,† and
Charlotte Glinge
1,†
1
The Heart Centre, Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, DK 2100 Copenhagen, Denmark
2
Department of Forensic Medicine, Faculty of Medical Sciences, University of Copenhagen, DK 2100 Copenhagen, Denmark
*
Author to whom correspondence should be addressed.
†
These authors contributed equally/share senior authorship.
J. Cardiovasc. Dev. Dis. 2026, 13(3), 127; https://doi.org/10.3390/jcdd13030127
Submission received: 16 January 2026 / Revised: 20 February 2026 / Accepted: 2 March 2026 / Published: 10 March 2026
(This article belongs to the Special Issue Feature Review Papers in the ‘Genetics’ Section)
Browse Figures
Versions Notes

Abstract

Myocardial infarction (MI) remains a leading cause of morbidity and mortality worldwide, which can result in severe complications such as cardiac arrhythmia, heart failure, and sudden cardiac death. Genetic factors contribute to MI etiology and have been studied through genome-wide association studies (GWAS). This systematic review aims to summarize all GWAS of MI reporting single-nucleotide polymorphisms (SNPs) reaching genome-wide significance (p < 5 × 10−8) and elucidate on their biological relevance and potential clinical utility. A systematic review following PRISMA guidelines was conducted using PubMed and the GWAS Catalog to identify eligible studies. This review included nine GWAS published between 2007 and 2023, conducted in both European and non-European cohorts. GWAS have identified multiple loci associated with MI, pinpointing potential biological pathways underlying MI, and potential therapeutic targets and enhancing risk prediction. Nonetheless, significant challenges remain, particularly the underrepresentation of diverse ancestries and the need for functional follow-up studies to define causal variants and clarify the mechanisms linking genetic variation to MI pathogenesis.

1. Introduction

Myocardial infarction (MI) remains a worldwide challenge for health and social care systems, since it is a leading cause of death with severe complications such as cardiac arrhythmia, heart failure, and sudden cardiac death [1,2,3,4]. The development of MI is influenced by both environmental and genetic factors. MI can present as early-onset, which is often indicative of an underlying genetic predisposition [5,6]. Traditional risk factors such as smoking, hypertension, and diabetes have long been established risk factors for MI [4]. Genetic predisposition to MI was first implicated after family and twin studies observed aggregation of MI within families [7,8]. Initially, MI was considered a monogenic disorder caused by rare variants in genes such as LDLR, APOB, and PCSK9, causing familial hypercholesterolemia [9]. The genetic architecture of MI is more complex than initially thought. Although common variants identified through genome-wide association studies (GWAS) account for an estimated 30–40% of MI heritability, they explain only a fraction of the overall genetic contribution [10,11]. The remaining “missing heritability” likely resides in rare variants of larger effect, gene–environment interactions, structural variation, and epigenetic modifications that are not fully captured by standard GWAS approaches [12]. It could be speculated that MI follows an omnigenic model, in which all genes expressed in relevant tissues may contribute to the pathophysiology [13]. To elucidate this omnigenic model of MI, genome-wide association studies (GWAS) have become essential. GWAS examine the genome in a hypothesis-free manner to identify common variants associated with MI [14]. MI was one of the earliest and most comprehensively studied phenotypes through GWAS approaches [15].
GWAS compare the allele frequency of common variants, or single-nucleotide polymorphisms (SNP), across the entire genome between groups of individuals with shared ancestry, usually a group with a particular disease or trait (cases) and a control group without it. For example, MI cases and controls without MI (Figure 1) [14]. Shared ancestry is essential, as allele frequencies vary across populations with different ancestral backgrounds [16]. After comparing allele frequencies between MI cases and controls, SNPs that occur significantly more frequently in MI cases are considered associated with MI. Given the large number of SNPs across the genome, multiple testing correction is performed [17]. Therefore, an SNP is considered genome-wide significant when it has a p-value of p < 5 × 10−8. These genome-wide significant SNPs pinpoint loci associated with MI. A locus (plural: loci) is a topological reference point referring to a region on the chromosome. These genomic loci can span up to hundreds of kilobases, containing coding regions, encoding for proteins, and non-coding regions that regulate gene expression [18,19]. Notably, the majority of GWAS-identified SNPs are located in non-coding regions, highlighting the importance of regulatory elements in disease susceptibility.
An SNP significantly associated with MI is not necessarily a causal variant, as SNPs can be in linkage disequilibrium (LD) with each other. This means that these SNPs are statistically associated and tend to be inherited together in a population because of their physical proximity on the chromosome [26]. Therefore, an SNP identified with GWAS may not be causal itself but could be in LD with the causal variant. Determining what variant is causal requires functional research. First, fine-mapping pinpoints the likely causal variants among SNPs in LD [20], followed by functional annotation to determine the biological relevance of the variants [21]. Variants are then linked to target genes using approaches such as expression quantitative trait locus (eQTL) mapping and transcriptome-wide association studies (TWAS) [22]. Finally, these genes can be connected to molecular pathways, and experimental validation can be performed [23].
Insights into the genes and molecular pathways underlying MI can have a clinical impact by identifying potential treatment targets and improving personalized risk prediction of MI in individuals [23]. Polygenic risk scores (PRS) are generated to identify individuals at elevated risk for MI. It enables the identification of those individuals even before clinical symptoms appear [24]. This offers opportunities for early interventions, personalized prevention strategies, and refined risk stratification beyond traditional factors. A PRS is calculated using the effect size of SNPs identified in GWAS [27].
This systematic review aims to summarize all GWAS of MI reporting single-nucleotide polymorphisms (SNPs) reaching genome-wide significance (p < 5 × 10−8) and elucidate on their biological relevance and potential clinical utility.

2. Materials and Methods

This systematic review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (see Supplementary Materials) and was registered in the Open Science Framework (OSF) (Registration number: nztkh) [28].
Studies were included in this systematic review when (1) a GWAS of MI was performed, defined as a GWAS comparing MI cases to controls without MI, and (2) the identified SNPs were genome-wide significant (p < 5 × 10−8). Two reviewers independently performed the search for eligible studies in the PubMed database and the GWAS Catalog, which was last updated on 1 October 2025.
The GWAS Catalog is the online catalog of GWAS hosted by the National Human Genome Research Institute. The catalog was established to provide a single reliable and freely available database of SNPs associated with specific traits and diseases. Studies are included in the GWAS Catalog when (1) it analyses the human genome without limiting to candidate genes, (2) includes a primary GWAS analysis (defined as “array-based genotyping and analysis of 100,000+ pre-QC SNPs selected to tag variation across the genome and without regard to gene content”), and (3) was published in English [29].
The SNPs reported in this review are the genome-wide significant SNPs reported by the GWAS Catalog. The GWAS Catalog reported the SNPs in genome construct hg38 as follows: When a combined p-value was not reported, the p-value and effect size from the largest sample size were reported (as long as the samples showed p < 1 × 10−5 in initial and replication samples). When no replication was performed, the SNPs identified in the discovery stage were reported. When the SNP was the most significant SNP from an independent locus and when previously known SNPs (at the time of publication) met the genome-wide significance threshold, even without replication, they were reported.

3. Results

The search for MI GWAS yielded nine eligible studies published in a period of 17 years (from 2007 to 2023) (Figure 2 and Table 1). Five European studies and four non-European studies were performed. The study characteristics are shown in Table 1. Together, the studies identified 198 genome-wide significant SNPs on independent loci, including 110 reported in European and 144 in non-European cohorts (Tables S1 and S2).
In 2007, the first GWAS of MI in European cohorts that identified a genome-wide significant SNP was performed [30]. They identified the common variant rs10757278 on chromosome 9p21, which contains the sequence encoding for CDKN2A/B, a tumor-suppressor gene regulating cell growth and division, whose association with MI was unknown before [37]. Currently, this locus, 9p21.3, is the most replicated associated locus with MI (Table S1). Subsequent studies in European cohorts identified more genome-wide significant variants associated with MI [5,31,33], including a variant on the ABO locus [31], encoding for proteins related to the blood group system [38], and the variant rs6941513 near QKI, encoding for a protein that is a regulator of pre-mRNA alternative splicing, which is highly expressed in adult and developing hearts [39]. Multiple variants identified in these GWAS were previously identified as variants associated with coronary artery disease (CAD), the primary underlying condition leading to MI, which explains the observed overlap in variants associated with CAD and MI [40].
In recent years, consortia have been formed, such as Coronary Artery Disease Genetics Consortium (C4D), Coronary Artery Disease Genome-Wide Replication and Meta-Analysis (CARDIoGRAM) Consortium (merged in 2013 to CARDIoGRAMplusC4D) and the Myocardial Infarction Genetics Consortium, and large biobanks have been established [41,42,43]. This enabled the study of bigger cohorts, which increased the statistical power of GWAS. For example, the UK Biobank is an advanced biobank consisting of data on over 500,000 individuals in the UK and is available through its public website [44]. The most recently published GWAS of MI in European cohorts used this biobank, resulting in a cohort of 17,505 cases and 454,212 controls. The study identified 1966 SNPs on 31 loci with significant genome-wide association with MI. They replicated known variants for MI, on 9p21, and loci encoding for LPA and SORT1, and they identified eight new loci with genome-wide significance for MI. They subsequently confirmed the association of a locus on chromosome 1p21.3 harboring SLC44A3 with MI in the Biobank Japan [35].
In 2011, the first GWAS of MI in non-European cohorts that identified a genome-wide significant SNP was performed. They identified a genome-wide significant variant on chromosome 5p15.3 that acts as a protective factor for MI [25]. Subsequent studies in non-European cohorts identified additional variants and loci associated with MI. Many of these overlapped with loci previously reported in European populations, including regions harboring LPA, PHACTR1, CELSR2, as well as the most frequently replicated locus 9p21 [35]. However, some identified variants and loci were only identified in European cohorts, for example, the locus harboring APOE [35], or only in non-European cohorts, for example, the locus harboring ALDH2 [36]. This underscores the importance of conducting GWAS of cohorts representing diverse ancestries. To date, GWAS of MI primarily focused on populations from European, middle Eastern, and Asian ancestry. Performing GWAS of cohorts from other ancestries will further maximize gene discovery and reduce the health disparities between European and non-European populations [45].

3.1. Associated Pathways and Intermediate Phenotypes

Multiple pathophysiologic mechanisms contribute to the development of atherosclerosis and ultimately MI, including dysregulation of lipid metabolism, diabetes, hypertension, and chronic inflammation [46]. GWAS of MI have clarified this complexity by identifying MI-associated loci enriched for genes governing metabolic, inflammatory, and vascular pathways (Figure 3) [46].
Atherosclerosis is initiated by endothelial dysfunction, which facilitates the accumulation of lipids such as low-density lipoprotein (LDL) within the arterial wall. This lipid deposition triggers an inflammatory response that further exacerbates endothelial dysfunction and lipid dysregulation, thereby promoting the progression, destabilization, and eventual rupture of atherosclerotic plaques [47]. GWAS of MI have identified multiple loci harboring genes involved in lipid metabolism, including ABO, APOE, LDLR, and LPA [35], as well as genes related to immune response and inflammation, such as FES, IL6R, and C2.
Moreover, diabetes and hypertension further accelerate plaque development and thrombosis. Diabetes promotes endothelial dysfunction through chronic hyperglycaemia, oxidative stress, and low-grade inflammation. Hypertension contributes via mechanical stress on the vessel wall, increased oxidative stress, and activation of inflammasome pathways, thereby enhancing the production of pro-inflammatory mediators [47]. Consistently, GWAS of MI have identified loci containing genes associated with diabetes, including ATXN2 and THADA, and with hypertension such as ARHGAP42, ATP2B1, and NOS3.
Collectively, these interrelated processes increase susceptibility to MI. Notably, many genes mapped to MI-associated GWAS loci are implicated in these upstream cardiometabolic and inflammatory pathways, suggesting that most identified variants influence disease predisposition through modulation of chronic pathophysiologic mechanisms rather than through direct involvement in the acute infarction event itself.
These pathophysiologic mechanisms contributing to the development of MI influence quantifiable biological traits, often referred to as intermediate phenotypes, which serve as a mechanistic bridge between genetic variation and MI risk. Studying intermediate phenotypes, and the overlap between MI-associated variants and variants associated with these traits, may provide a more direct understanding of the biological processes underlying MI, early-stage MI, and atherosclerosis progression [48].
These findings illustrate that MI can be seen as a complex network of genetically influenced intermediate phenotypes, which must be understood to translate GWAS findings into biological mechanisms.
Jcdd 13 00127 g003
Figure 3. MI-associated genes and related pathophysiologic pathways and mechanisms. The GWAS of MI reported or mapped 181 genes. The pathways or systems the genes play a role in are shown in red. MI, Myocardial infarction (Figure concept inspired by Erdmann et al. [10,49]).
Figure 3. MI-associated genes and related pathophysiologic pathways and mechanisms. The GWAS of MI reported or mapped 181 genes. The pathways or systems the genes play a role in are shown in red. MI, Myocardial infarction (Figure concept inspired by Erdmann et al. [10,49]).
Jcdd 13 00127 g003

3.2. Loci in Coding and Non-Coding Regions

GWAS have identified MI-associated loci spanning both coding and non-coding regions, underscoring how variants in sequences encoding for proteins and regulating gene expression collectively shape MI susceptibility. The genes mapped to these variants are shown in Tables S1 and S2.
An example of an MI-associated loci in a non-coding region, is the most replicated locus, 9p21, that is harboring CDKN2B-AS1. CDKN2B-AS1 is translated into long non-coding RNAs (lncRNA) that silence other genes in the CDKN2B-CDKN2A cluster, thereby regulating the gene expression of the cluster [37]. At first, the relation of this potential mechanism to the MI mechanism was unknown. By performing a functional study, Li et al. found that the CDKN2B-AS1 lncRNA inhibits ADAM10 transcription, which promotes the efflux of cholesterol and prevents the atherosclerotic inflammatory response when active. Therefore, CDKN2B-AS1 can prevent atherosclerotic formation, a well-known cause of MI [40]. This demonstrates how functional studies can elucidate the role of a previously unknown mechanisms to MI. Furthermore, a study by Bayoglu et al. found that loci encoding for CDKN2B-AS1 are associated with increased susceptibility to hypertension development [50]. Showing that CDKN2B-AS1 may be involved in multiple mechanisms contributing to MI.
An example of an SNP in coding regions is the SNP rs368803408 on a locus harboring the sequence for the low-density lipoprotein receptor (LDLR). Variants in LDLR, which mediates the uptake of cholesterol, are known to cause monogenic familial hypercholesterolemia, which is strongly associated with MI [9].
Life threatening arrhythmias may occur in the setting of acute MI [51]. It is thought that myocardial ischemia and subsequent scar formation are the primary mechanisms underlying arrhythmogenesis following acute MI [52]. However, not all MI patients develop arrhythmias. Factors such as infarct location, patient age and comorbidities are thought to influence this [53]. Additionally genetic factors may play a role in arrhythmogenesis following MI as well. For example, three SNPs rs9982601, rs928758, and rs28451064, identified in both European and non-European cohorts are located on the locus that harbors the sequence encoding for KCNE2. KCNE2 is a voltage-gated potassium channel gene expressed in muscles and the heart that regulates, among others, smooth muscle contraction, heart rate, neurotransmitter release, and insulin secretion [54]. Loss-of-function KCNE2 variants are associated with long-QT syndrome and arrhythmia, including atrial fibrillation [55]. These three SNPs, together with other ion-channel-encoding genes (Figure 3), point to specific pathways that may contribute to proarrhythmic susceptibility in MI. The fact that these variants are identified in GWAS of MI could be explained by the possibility that KCNE2 variants may not only influence the severity of arrhythmias that arise secondary to MI but also suggest an underlying predisposition to both arrhythmias and MI itself. This highlights the need for further fundamental research to substantiate these findings.

3.3. Treatment Targets

GWAS of MI, in combination with, amongst others, Mendelian randomisation, have identified MI-associated mechanisms that were already targeted by established treatments, such as Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and statins, as well as potential novel treatment targets [56,57].
PCSK9 regulates lipid homeostasis through binding to the low-density lipoprotein (LDL)-receptor and targeting it for degradation, resulting in an increased LDL-cholesterol concentration in the circulation [58,59,60]. High levels of PCSK9 are significantly associated with increased risk of cardiovascular disease [61,62]. Inhibition of PCSK9 has shown to reduce LDL-cholesterol by 60% [63], and can reduce risk of MI [64].
The first example of a treatment target pinpointed by GWAS results is interleukin-6 (IL-6). GWAS have identified variants at the IL6R locus associated with MI [35,36]. Inhibition of the IL-6 receptor (IL-6R) is suggested to have cardiovascular benefit. The CANTOS trial showed that inhibition of interleukin 1-beta (IL-1β), a component in the IL-6 signaling pathway, with a monoclonal antibody reduces cardiovascular event rates in patients with a history of coronary heart disease [65]. Early-phase trials of Tocilizumab, an IL-6R inhibitor originally approved for rheumatoid arthritis, have shown promising results for cardiovascular effects [66].
Another potential target identified by GWAS is ADAMTS7 [36], which encodes a metalloprotease involved in extracellular matrix degradation and atherosclerosis progression [31]. Its causal role in atherosclerosis has been confirmed in vivo [67], and inhibitors of ADAMTS7 are currently being explored in preclinical studies [68,69].

3.4. Polygenic Risk Score for Early Risk Prediction of MI

PRS are generated to estimate an individual’s risk for MI, based on the MI-associated variants in the genome of the individual. A PRS is calculated as the sum of the weighted effect size of SNPs associated with MI, regardless of their individual genome-wide significance [27]. Therefore, a PRS captures the polygenic architecture of complex and common traits, such as MI, more comprehensively than a genetic risk score (GRS). A GRS is typically calculated by the sum of the effect size of the most significant variants, so not all identified SNPs [70]. As the predictive power of PRS improves with the identification of additional SNPs of larger effect sizes, its integration into clinical practice could advance precision medicine. GWAS of MI have identified SNPs with effect sizes up to 1.39 (95% CI, 1.33–1.44) (Tables S1 and S2).
Several studies have evaluated PRS in MI and CAD cohorts. Khera et al. showed the potential of a genome-wide PRS (comprising 6.6 million SNPs) for improving CAD risk prediction [24]. They identified 8% of the cohort at greater than 3-fold increased risk for CAD. This PRS was derived from a GWAS with 184,305 participants and was validated in the UK Biobank [44,71].

3.5. Combining Polygenic Risk Score with Clinical Risk Scores

Currently used clinical risk scores for recurrence of MI, such as GRACE (Global Registry of Acute Coronary Events) and TIMI (Thrombolysis in Myocardial Infarction) Risk scores, use commonly available clinical and laboratory variables that do not include genetic factors [72]. To improve risk prediction for MI, PRS can be combined with these clinical risk models. A study on PRS for cardiovascular diseases showed that combining PRS with clinical risk models significantly improved the identification of individuals who experienced a major adverse cardiovascular event. This increase was especially seen in younger individuals [73]. Adding PRS to standard clinical risk models of MI could therefore improve risk prediction for MI.

3.6. Limitations

Besides the limitations discussed throughout the chapters, it is important to highlight additional factors in GWAS of MI that could affect interpretation of GWAS results.
Not accounting for non-genetic risk factors, such as smoking, drug and alcohol abuse, in GWAS of MI may introduce confounding, as these environmental factors can increase MI risk and alter gene expression [74,75]. Therefore, observed genetic associations may represent gene–environment interactions, where genetic effects on MI risk are modified by environmental factors. For example, a genetic variant may only be associated with MI in individuals who smoke [76,77].
The definition of MI and the selection of cases and controls influence the studied phenotype and, consequently, GWAS results. The definition of MI differed between studies, ranging from diagnosis through ECG manifestations and changes in biomarkers [34] to self-reported MI (Table 1) [35]. Therefore, it is important to recognize that, although all included GWAS-identified variants associated with MI, some variants may reflect susceptibility to specific MI phenotypes captured in each study.

4. Conclusions

Over the past two decades, nine GWAS have identified genome-wide significant loci associated with MI, pinpointing potential biological pathways underlying MI and potential therapeutic targets and improving genetic risk prediction. Therefore, identification of MI-associated loci through GWAS of MI has led toward pathway-level understanding of MI. Nonetheless, significant challenges remain, particularly the underrepresentation of diverse ancestries and the need for functional follow-up studies to define causal variants and clarify the mechanisms linking genetic variation to MI pathogenesis.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/jcdd13030127/s1, Table S1: GWAS significant SNPs associated with MI in European cohorts and their characteristics; Table S2: GWAS significant SNPs associated with MI in non-European cohorts and their characteristics.

Author Contributions

Conceptualization, J.T.-H. and C.G.; methodology, J.T.-H. and C.G.; formal analysis, I.P.T. and C.G.; investigation, I.P.T. and C.G.; data curation, I.P.T.; writing—original draft preparation, I.P.T. and C.G.; writing—review and editing, I.P.T., R.J., T.E., J.T.-H. and C.G.; visualization, I.P.T.; supervision, C.G. and J.T.-H.; All authors have read and agreed to the published version of the manuscript.

Funding

CG was supported by the Danish Cardiovascular Academy, which is funded by the Novo Nordisk Foundation, grant number CPD5Y-2022003-HF and The Danish Heart Foundation. The funders had no role in the design, conduct of the study or in the decision to submit the paper for publication.

Data Availability Statement

The original data presented in the study are openly available at https://www.ebi.ac.uk/gwas/home (1 October 2025).

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript:
CADCoronary Artery Disease
CARDIoGRAMCoronary Artery Disease Genome-Wide Replication and Meta-Analysis
C4DCoronary Artery Disease Genetics Consortium
eQTLExpression quantitative trait locus
FHFamilial hypercholesterolemia
GRACEGlobal Registry of Acute Coronary Events
GRSGenetic risk score
GWASGenome-wide association study
IL-1βInterleukin 1-beta
IL-6Interleukin-6
LDLinkage disequilibrium
LDLLow-density lipoprotein
LDLRLow-density lipoprotein receptor
lncRNALong non-coding RNA
MIMyocardial infarction
PCAPrincipal component analysis
PSCK9Proprotein convertase subtilisin/kexin type 9
PRSPolygenic risk score
SNPSingle-nucleotide polymorphism
TIMIThrombolysis in Myocardial Infarction
TWASTranscriptome-wide association studies

References

  1. Thygesen, K.; Alpert, J.S.; Jaffe, A.S.; Chaitman, B.R.; Bax, J.J.; Morrow, D.A.; White, H.D.; Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF). Task Force for the Universal Definition of Myocardial Infarction Fourth Universal Definition of Myocardial Infarction (2018). Circulation 2018, 138, e618–e651. [Google Scholar] [CrossRef]
  2. Reed, G.W.; Rossi, J.E.; Cannon, C.P. Acute Myocardial Infarction. Lancet 2017, 389, 197–210. [Google Scholar] [CrossRef] [PubMed]
  3. Könemann, H.; Dagres, N.; Merino, J.L.; Sticherling, C.; Zeppenfeld, K.; Tfelt-Hansen, J.; Eckardt, L. Spotlight on the 2022 ESC Guideline Management of Ventricular Arrhythmias and Prevention of Sudden Cardiac Death: 10 Novel Key Aspects. EP Europace 2023, 25, euad091. [Google Scholar] [CrossRef]
  4. Byrne, R.A.; Rossello, X.; Coughlan, J.J.; Barbato, E.; Berry, C.; Chieffo, A.; Claeys, M.J.; Dan, G.-A.; Dweck, M.R.; Galbraith, M.; et al. 2023 ESC Guidelines for the Management of Acute Coronary Syndromes. Eur. Heart J. 2023, 44, 3720–3826. [Google Scholar] [CrossRef]
  5. Myocardial Infarction Genetics Consortium; Kathiresan, S.; Voight, B.F.; Purcell, S.; Musunuru, K.; Ardissino, D.; Mannucci, P.M.; Anand, S.; Engert, J.C.; Samani, N.J.; et al. Genome-Wide Association of Early-Onset Myocardial Infarction with Single Nucleotide Polymorphisms and Copy Number Variants. Nat. Genet. 2009, 41, 334–341. [Google Scholar] [CrossRef]
  6. Jeon, Y.; Jeon, S.; Choi, W.-H.; An, K.; Choi, H.; Kim, B.-C.; Kim, W.; Lee, S.Y.; Bae, J.-W.; Hwang, J.-Y.; et al. Genome-Wide Analyses of Early-Onset Acute Myocardial Infarction Identify 29 Novel Loci by Whole Genome Sequencing. Hum. Genet. 2023, 142, 231–243. [Google Scholar] [CrossRef]
  7. Roncaglioni, M.C.; Santoro, L.; D’Avanzo, B.; Negri, E.; Nobili, A.; Ledda, A.; Pietropaolo, F.; Franzosi, M.G.; La Vecchia, C.; Feruglio, G.A. Role of Family History in Patients with Myocardial Infarction. An Italian Case-Control Study. GISSI-EFRIM Investigators. Circulation 1992, 85, 2065–2072. [Google Scholar] [CrossRef]
  8. Hübinette, A.; Cnattingius, S.; Ekbom, A.; de Faire, U.; Kramer, M.; Lichtenstein, P. Birthweight, Early Environment, and Genetics: A Study of Twins Discordant for Acute Myocardial Infarction. Lancet 2001, 357, 1997–2001. [Google Scholar] [CrossRef] [PubMed]
  9. Brænne, I.; Kleinecke, M.; Reiz, B.; Graf, E.; Strom, T.; Wieland, T.; Fischer, M.; Kessler, T.; Hengstenberg, C.; Meitinger, T.; et al. Systematic Analysis of Variants Related to Familial Hypercholesterolemia in Families with Premature Myocardial Infarction. Eur. J. Hum. Genet. 2016, 24, 191–197. [Google Scholar] [CrossRef] [PubMed]
  10. Erdmann, J.; Kessler, T.; Munoz Venegas, L.; Schunkert, H. A Decade of Genome-Wide Association Studies for Coronary Artery Disease: The Challenges Ahead. Cardiovasc. Res. 2018, 114, 1241–1257. [Google Scholar] [CrossRef]
  11. Khera, A.V.; Kathiresan, S. Genetics of Coronary Artery Disease: Discovery, Biology and Clinical Translation. Nat. Rev. Genet. 2017, 18, 331–344. [Google Scholar] [CrossRef]
  12. Cerrone, M.; Remme, C.A.; Tadros, R.; Bezzina, C.R.; Delmar, M. Beyond the One Gene–One Disease Paradigm: Complex Genetics and Pleiotropy in Inheritable Cardiac Disorders. Circulation 2019, 145, 595–610. [Google Scholar] [CrossRef]
  13. Boyle, E.A.; Li, Y.I.; Pritchard, J.K. An Expanded View of Complex Traits: From Polygenic to Omnigenic. Cell 2017, 169, 1177–1186. [Google Scholar] [CrossRef]
  14. Hirschhorn, J.N.; Daly, M.J. Genome-Wide Association Studies for Common Diseases and Complex Traits. Nat. Rev. Genet. 2005, 6, 95–108. [Google Scholar] [CrossRef] [PubMed]
  15. Ozaki, K.; Tanaka, T. Genome-Wide SNP Association Study to Identify Genes Related to Myocardial Infarction and Their Functional Analyses. Tanpakushitsu Kakusan Koso Protein Nucleic Acid Enzym. 2004, 49, 2215–2221. [Google Scholar]
  16. Colonna, V.; Ayub, Q.; Chen, Y.; Pagani, L.; Luisi, P.; Pybus, M.; Garrison, E.; Xue, Y.; Tyler-Smith, C.; The 1000 Genomes Project Consortium. Human Genomic Regions with Exceptionally High Levels of Population Differentiation Identified from 911 Whole-Genome Sequences. Genome Biol. 2014, 15, R88. [Google Scholar] [CrossRef]
  17. Pe’er, I.; Yelensky, R.; Altshuler, D.; Daly, M.J. Estimation of the Multiple Testing Burden for Genomewide Association Studies of Nearly All Common Variants. Genet. Epidemiol. 2008, 32, 381–385. [Google Scholar] [CrossRef]
  18. Uffelmann, E.; Huang, Q.Q.; Munung, N.S.; de Vries, J.; Okada, Y.; Martin, A.R.; Martin, H.C.; Lappalainen, T.; Posthuma, D. Genome-Wide Association Studies. Nat. Rev. Methods Primers 2021, 1, 59. [Google Scholar] [CrossRef]
  19. Stapley, J.; Feulner, P.G.D.; Johnston, S.E.; Santure, A.W.; Smadja, C.M. Recombination: The Good, the Bad and the Variable. Philos. Trans. R. Soc. B Biol. Sci. 2017, 372, 20170279. [Google Scholar] [CrossRef]
  20. Schaid, D.J.; Chen, W.; Larson, N.B. From Genome-Wide Associations to Candidate Causal Variants by Statistical Fine-Mapping. Nat. Rev. Genet. 2018, 19, 491–504. [Google Scholar] [CrossRef] [PubMed]
  21. Pilalis, E.; Zisis, D.; Andrinopoulou, C.; Karamanidou, T.; Antonara, M.; Stavropoulos, T.G.; Chatziioannou, A. Genome-Wide Functional Annotation of Variants: A Systematic Review of State-of-the-Art Tools, Techniques and Resources. Front. Pharmacol. 2025, 16, 1474026. [Google Scholar] [CrossRef]
  22. Mai, J.; Lu, M.; Gao, Q.; Zeng, J.; Xiao, J. Transcriptome-Wide Association Studies: Recent Advances in Methods, Applications and Available Databases. Commun. Biol. 2023, 6, 899. [Google Scholar] [CrossRef] [PubMed]
  23. Cano-Gamez, E.; Trynka, G. From GWAS to Function: Using Functional Genomics to Identify the Mechanisms Underlying Complex Diseases. Front. Genet. 2020, 11, 424. [Google Scholar] [CrossRef]
  24. Khera, A.V.; Chaffin, M.; Aragam, K.G.; Haas, M.E.; Roselli, C.; Choi, S.H.; Natarajan, P.; Lander, E.S.; Lubitz, S.A.; Ellinor, P.T.; et al. Genome-Wide Polygenic Scores for Common Diseases Identify Individuals with Risk Equivalent to Monogenic Mutations. Nat. Genet. 2018, 50, 1219–1224. [Google Scholar] [CrossRef]
  25. Aoki, A.; Ozaki, K.; Sato, H.; Takahashi, A.; Kubo, M.; Sakata, Y.; Onouchi, Y.; Kawaguchi, T.; Lin, T.-H.; Takano, H.; et al. SNPs on Chromosome 5p15.3 Associated with Myocardial Infarction in Japanese Population. J. Hum. Genet. 2011, 56, 47–51. [Google Scholar] [CrossRef]
  26. International HapMap Consortium. The International HapMap Project. Nature 2003, 426, 789–796. [Google Scholar] [CrossRef]
  27. Choi, S.W.; Mak, T.S.-H.; O’Reilly, P.F. Tutorial: A Guide to Performing Polygenic Risk Score Analyses. Nat. Protoc. 2020, 15, 2759–2772. [Google Scholar] [CrossRef] [PubMed]
  28. Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; et al. The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews. BMJ 2021, 372, n71. [Google Scholar] [CrossRef] [PubMed]
  29. EMBL. EBI GWAS Catalog: Methods/Criteria; EMBL: Heidelberg, Germany, 2025. [Google Scholar]
  30. Helgadottir, A.; Thorleifsson, G.; Manolescu, A.; Gretarsdottir, S.; Blondal, T.; Jonasdottir, A.; Jonasdottir, A.; Sigurdsson, A.; Baker, A.; Palsson, A.; et al. A Common Variant on Chromosome 9p21 Affects the Risk of Myocardial Infarction. Science 2007, 316, 1491–1493. [Google Scholar] [CrossRef]
  31. Reilly, M.P.; Li, M.; He, J.; Ferguson, J.F.; Stylianou, I.M.; Mehta, N.N.; Burnett, M.S.; Devaney, J.M.; Knouff, C.W.; Thompson, J.R.; et al. Identification of ADAMTS7 as a Novel Locus for Coronary Atherosclerosis and Association of ABO with Myocardial Infarction in the Presence of Coronary Atherosclerosis: Two Genome-Wide Association Studies. Lancet 2011, 377, 383–392. [Google Scholar] [CrossRef]
  32. Hirokawa, M.; Morita, H.; Tajima, T.; Takahashi, A.; Ashikawa, K.; Miya, F.; Shigemizu, D.; Ozaki, K.; Sakata, Y.; Nakatani, D.; et al. A Genome-Wide Association Study Identifies PLCL2 and AP3D1-DOT1L-SF3A2 as New Susceptibility Loci for Myocardial Infarction in Japanese. Eur. J. Hum. Genet. 2015, 23, 374–380. [Google Scholar] [CrossRef]
  33. Dehghan, A.; Bis, J.C.; White, C.C.; Smith, A.V.; Morrison, A.C.; Cupples, L.A.; Trompet, S.; Chasman, D.I.; Lumley, T.; Völker, U.; et al. Genome-Wide Association Study for Incident Myocardial Infarction and Coronary Heart Disease in Prospective Cohort Studies: The CHARGE Consortium. PLoS ONE 2016, 11, e0144997. [Google Scholar] [CrossRef]
  34. Wakil, S.M.; Ram, R.; Muiya, N.P.; Mehta, M.; Andres, E.; Mazhar, N.; Baz, B.; Hagos, S.; Alshahid, M.; Meyer, B.F.; et al. A Genome-Wide Association Study Reveals Susceptibility Loci for Myocardial Infarction/Coronary Artery Disease in Saudi Arabs. Atherosclerosis 2016, 245, 62–70. [Google Scholar] [CrossRef]
  35. Hartiala, J.A.; Han, Y.; Jia, Q.; Hilser, J.R.; Huang, P.; Gukasyan, J.; Schwartzman, W.S.; Cai, Z.; Biswas, S.; Trégouët, D.-A.; et al. Genome-Wide Analysis Identifies Novel Susceptibility Loci for Myocardial Infarction. Eur. Heart J. 2021, 42, 919–933. [Google Scholar] [CrossRef]
  36. Al-Ali, A.K.; Al-Rubaish, A.M.; Alali, R.A.; Almansori, M.S.; Al-Jumaan, M.A.; Alshehri, A.M.; Al-Madan, M.S.; Vatte, C.; Cherlin, T.; Young, S.; et al. Uncovering Myocardial Infarction Genetic Signatures Using GWAS Exploration in Saudi and European Cohorts. Sci. Rep. 2023, 13, 21866. [Google Scholar] [CrossRef] [PubMed]
  37. PubChem. CDKN2A—Cyclin Dependent Kinase Inhibitor 2A (Human). Available online: https://pubchem.ncbi.nlm.nih.gov/gene/CDKN2A/human (accessed on 23 October 2025).
  38. Romanos-Sirakis, E.C.; Desai, D. ABO Blood Group System. In StatPearls; StatPearls Publishing: Treasure Island, FL, USA, 2025. [Google Scholar]
  39. Chen, X.; Liu, Y.; Xu, C.; Ba, L.; Liu, Z.; Li, X.; Huang, J.; Simpson, E.; Gao, H.; Cao, D.; et al. QKI Is a Critical Pre-mRNA Alternative Splicing Regulator of Cardiac Myofibrillogenesis and Contractile Function. Nat. Commun. 2021, 12, 89. [Google Scholar] [CrossRef] [PubMed]
  40. Samani, N.J.; Erdmann, J.; Hall, A.S.; Hengstenberg, C.; Mangino, M.; Mayer, B.; Dixon, R.J.; Meitinger, T.; Braund, P.; Wichmann, H.-E.; et al. Genomewide Association Analysis of Coronary Artery Disease. N. Engl. J. Med. 2007, 357, 443–453. [Google Scholar] [CrossRef]
  41. Coronary Artery Disease (C4D) Genetics Consortium. A Genome-Wide Association Study in Europeans and South Asians Identifies Five New Loci for Coronary Artery Disease. Nat. Genet. 2011, 43, 339–344. [Google Scholar] [CrossRef]
  42. CARDIoGRAMplusC4D Consortium. Institution Outputs|Nature Index. Available online: https://www.nature.com/nature-index/institution-outputs/united-kingdom-uk/cardiogramplusc4d-consortium/5379a9cf140ba07b7e000000 (accessed on 23 October 2025).
  43. Myocardial Infarction Genetics Consortium (MIGen). Available online: https://www.nature.com/nature-index/institution-outputs/United%20States%20of%20America%20%28USA%29/Myocardial%20Infarction%20Genetics%20Consortium%20%28MIGen%29/537abcec140ba00166000002 (accessed on 23 October 2025).
  44. Sudlow, C.; Gallacher, J.; Allen, N.; Beral, V.; Burton, P.; Danesh, J.; Downey, P.; Elliott, P.; Green, J.; Landray, M.; et al. UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age. PLoS Med. 2015, 12, e1001779. [Google Scholar] [CrossRef]
  45. Misra, S. Ethnic Diversity in Precision Medicine: A Reality or an Aspiration? Diabetologia 2025, 68, 2449–2464. [Google Scholar] [CrossRef] [PubMed]
  46. Frangogiannis, N.G. Pathophysiology of Myocardial Infarction. Compr. Physiol. 2015, 5, 1841–1875. [Google Scholar] [CrossRef] [PubMed]
  47. Liu, M.; Mo, D.-G.; Bai, J.-X.; Han, Q.-F.; Yao, H.-C. Three-Dimensional Perspectives on Inflammatory Regulation in Coronary Atherosclerosis: Integrated Mechanisms of Endothelial Priming, Lipid Metabolism, and Cytokine Synergy. Rev. Cardiovasc. Med. 2026, 27, 42822. [Google Scholar] [CrossRef] [PubMed]
  48. Rao, F.; Zhang, L.; O’Connor, D.T. Complex Trait Genetics: The Role of Mechanistic “Intermediate Phenotypes” and Candidate Genetic Loci. J. Am. Coll. Cardiol. 2008, 52, 166–168. [Google Scholar] [CrossRef][Green Version]
  49. Thierry, I. Created in BioRender. 2026. Available online: https://BioRender.Com/9x2r9n2 (accessed on 1 October 2025).
  50. Bayoglu, B.; Yuksel, H.; Cakmak, H.A.; Dirican, A.; Cengiz, M. Polymorphisms in the Long Non-Coding RNA CDKN2B-AS1 May Contribute to Higher Systolic Blood Pressure Levels in Hypertensive Patients. Clin. Biochem. 2016, 49, 821–827. [Google Scholar] [CrossRef]
  51. Glinge, C.; Lahrouchi, N.; Jabbari, R.; Tfelt-Hansen, J.; Bezzina, C.R. Genome-Wide Association Studies of Cardiac Electrical Phenotypes. Cardiovasc. Res. 2020, 116, 1620. [Google Scholar] [CrossRef]
  52. Frampton, J.; Ortengren, A.R.; Zeitler, E.P. Arrhythmias After Acute Myocardial Infarction. Yale J. Biol. Med. 2023, 96, 83–94. [Google Scholar] [CrossRef] [PubMed]
  53. Kurmi, P.; Patidar, A.; Patidar, S.; Yadav, U. Incidence and Prognostic Significance of Arrhythmia in Acute Myocardial Infarction Presentation: An Observational Study. Cureus 2024, 16, e71564. [Google Scholar] [CrossRef]
  54. KCNE2 Potassium Voltage-Gated Channel Subfamily E Regulatory Subunit 2 [Homo Sapiens (Human)]—Gene—NCBI. Available online: https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=DetailsSearch&Term=9992 (accessed on 1 October 2025).
  55. Roberts, J.D.; Krahn, A.D.; Ackerman, M.J.; Rohatgi, R.K.; Moss, A.J.; Nazer, B.; Tadros, R.; Gerull, B.; Sanatani, S.; Wijeyeratne, Y.D.; et al. Loss-of-Function KCNE2 Variants. Circ. Arrhythmia Electrophysiol. 2017, 10, e005282. [Google Scholar] [CrossRef]
  56. Turner, A.W.; Wong, D.; Dreisbach, C.N.; Miller, C.L. GWAS Reveal Targets in Vessel Wall Pathways to Treat Coronary Artery Disease. Front. Cardiovasc. Med. 2018, 5, 72. [Google Scholar] [CrossRef]
  57. Wu, J.; Fan, Q.; He, Q.; Zhong, Q.; Zhu, X.; Cai, H.; He, X.; Xu, Y.; Huang, Y.; Di, X. Potential Drug Targets for Myocardial Infarction Identified through Mendelian Randomization Analysis and Genetic Colocalization. Medicine 2023, 102, e36284. [Google Scholar] [CrossRef]
  58. Nassoury, N.; Blasiole, D.A.; Tebon Oler, A.; Benjannet, S.; Hamelin, J.; Poupon, V.; McPherson, P.S.; Attie, A.D.; Prat, A.; Seidah, N.G. The Cellular Trafficking of the Secretory Proprotein Convertase PCSK9 and Its Dependence on the LDLR. Traffic 2007, 8, 718–732. [Google Scholar] [CrossRef]
  59. Zhang, D.-W.; Garuti, R.; Tang, W.-J.; Cohen, J.C.; Hobbs, H.H. Structural Requirements for PCSK9-Mediated Degradation of the Low-Density Lipoprotein Receptor. Proc. Natl. Acad. Sci. USA 2008, 105, 13045–13050. [Google Scholar] [CrossRef]
  60. Seidah, N.G.; Awan, Z.; Chrétien, M.; Mbikay, M. PCSK9: A Key Modulator of Cardiovascular Health. Circ. Res. 2014, 114, 1022–1036. [Google Scholar] [CrossRef]
  61. Kheirkhah, A.; Lamina, C.; Kollerits, B.; Schachtl-Riess, J.F.; Schultheiss, U.T.; Forer, L.; Sekula, P.; Kotsis, F.; Eckardt, K.-U.; Kronenberg, F.; et al. PCSK9 and Cardiovascular Disease in Individuals with Moderately Decreased Kidney Function. Clin. J. Am. Soc. Nephrol. 2022, 17, 809–818. [Google Scholar] [CrossRef]
  62. Kheirkhah, A.; Lamina, C.; Rantner, B.; Kollerits, B.; Stadler, M.; Pohlhammer, J.; Klein-Weigel, P.; Fraedrich, G.; Kronenberg, F. Elevated Levels of Serum PCSK9 in Male Patients with Symptomatic Peripheral Artery Disease: The CAVASIC Study. Atherosclerosis 2021, 316, 41–47. [Google Scholar] [CrossRef] [PubMed]
  63. Libby, P.; Tokgözoğlu, L. Chasing LDL Cholesterol to the Bottom—PCSK9 in Perspective. Nat. Cardiovasc. Res. 2022, 1, 554–561. [Google Scholar] [CrossRef]
  64. Andreadou, I.; Tsoumani, M.; Vilahur, G.; Ikonomidis, I.; Badimon, L.; Varga, Z.V.; Ferdinandy, P.; Schulz, R. PCSK9 in Myocardial Infarction and Cardioprotection: Importance of Lipid Metabolism and Inflammation. Front. Physiol. 2020, 11, 602497. [Google Scholar] [CrossRef]
  65. Ridker, P.M.; Everett, B.M.; Thuren, T.; MacFadyen, J.G.; Chang, W.H.; Ballantyne, C.; Fonseca, F.; Nicolau, J.; Koenig, W.; Anker, S.D.; et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N. Engl. J. Med. 2017, 377, 1119–1131. [Google Scholar] [CrossRef]
  66. Kleveland, O.; Kunszt, G.; Bratlie, M.; Ueland, T.; Broch, K.; Holte, E.; Michelsen, A.E.; Bendz, B.; Amundsen, B.H.; Espevik, T.; et al. Effect of a Single Dose of the Interleukin-6 Receptor Antagonist Tocilizumab on Inflammation and Troponin T Release in Patients with Non-ST-Elevation Myocardial Infarction: A Double-Blind, Randomized, Placebo-Controlled Phase 2 Trial. Eur. Heart J. 2016, 37, 2406–2413. [Google Scholar] [CrossRef]
  67. Bauer, R.C.; Tohyama, J.; Cui, J.; Cheng, L.; Yang, J.; Zhang, X.; Ou, K.; Paschos, G.K.; Zheng, X.L.; Parmacek, M.S.; et al. Knockout of Adamts7, a Novel Coronary Artery Disease Locus in Humans, Reduces Atherosclerosis in Mice. Circulation 2015, 131, 1202–1213. [Google Scholar] [CrossRef]
  68. Meibom, D.; Wasnaire, P.; Beyer, K.; Broehl, A.; Cancho-Grande, Y.; Elowe, N.; Henninger, K.; Johannes, S.; Jungmann, N.; Krainz, T.; et al. BAY-9835: Discovery of the First Orally Bioavailable ADAMTS7 Inhibitor. J. Med. Chem. 2024, 67, 2907–2940. [Google Scholar] [CrossRef] [PubMed]
  69. Santamaria, S.; Buemi, F.; Nuti, E.; Cuffaro, D.; De Vita, E.; Tuccinardi, T.; Rossello, A.; Howell, S.; Mehmood, S.; Snijders, A.P.; et al. Development of a Fluorogenic ADAMTS-7 Substrate. J. Enzym. Inhib. Med. Chem. 2021, 36, 2160–2169. [Google Scholar] [CrossRef]
  70. Igo, R.P.; Kinzy, T.G.; Bailey, J.N.C. Genetic Risk Scores. Curr. Protoc. Hum. Genet. 2019, 104, e95. [Google Scholar] [CrossRef]
  71. Nikpay, M.; Goel, A.; Won, H.-H.; Hall, L.M.; Willenborg, C.; Kanoni, S.; Saleheen, D.; Kyriakou, T.; Nelson, C.P.; Hopewell, J.C.; et al. A Comprehensive 1000 Genomes-Based Genome-Wide Association Meta-Analysis of Coronary Artery Disease. Nat. Genet. 2015, 47, 1121–1130. [Google Scholar] [CrossRef] [PubMed]
  72. Rao, S.V.; O’Donoghue, M.L.; Ruel, M.; Rab, T.; Tamis-Holland, J.E.; Alexander, J.H.; Baber, U.; Baker, H.; Cohen, M.G.; Cruz-Ruiz, M.; et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients with Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2025, 151, e771–e862. [Google Scholar] [CrossRef]
  73. Samani, N.J.; Beeston, E.; Greengrass, C.; Riveros-McKay, F.; Debiec, R.; Lawday, D.; Wang, Q.; Budgeon, C.A.; Braund, P.S.; Bramley, R.; et al. Polygenic Risk Score Adds to a Clinical Risk Score in the Prediction of Cardiovascular Disease in a Clinical Setting. Eur. Heart J. 2024, 45, 3152–3160. [Google Scholar] [CrossRef]
  74. Thomas, D. Gene-Environment-Wide Association Studies: Emerging Approaches. Nat. Rev. Genet. 2010, 11, 259–272. [Google Scholar] [CrossRef]
  75. Zhang, M.; Hu, T.; Ma, T.; Huang, W.; Wang, Y. Epigenetics and Environmental Health. Front. Med. 2024, 18, 571–596. [Google Scholar] [CrossRef]
  76. Polfus, L.M.; Smith, J.A.; Shimmin, L.C.; Bielak, L.F.; Morrison, A.C.; Kardia, S.L.R.; Peyser, P.A.; Hixson, J.E. Genome-Wide Association Study of Gene by Smoking Interactions in Coronary Artery Calcification. PLoS ONE 2013, 8, e74642. [Google Scholar] [CrossRef]
  77. Hartiala, J.A.; Hilser, J.R.; Biswas, S.; Lusis, A.J.; Allayee, H. Gene-Environment Interactions for Cardiovascular Disease. Curr. Atheroscler. Rep. 2021, 23, 75. [Google Scholar] [CrossRef] [PubMed]
Jcdd 13 00127 g001
Figure 1. Overview of GWAS of MI workflow and its clinical implications. The GWAS workflow is shown in the gray boxes. The clinical implications of the GWAS results are shown in the white boxes. Genetic data are obtained for individuals with and without an MI phenotype. Genotyping of the genomes of the included individuals is performed. GWAS results are visualized in a Manhattan plot, with the y-axis representing −log10 p-values and the x-axis representing chromosomal positions. The effect sizes of associated SNPs are used for risk prediction with polygenic risk scores, which can be combined with clinical risk scores using non-genetic risk factors. The SNP variants associated with MI can be further analyzed by performing functional research. This can provide insights into biological mechanisms associated with MI and pinpoint potential treatment targets. EQTL, Expression quantitative trait locus; GWAS, Genome-wide association study; MI, Myocardial infarction; PRS, Polygenic risk score; TWAS, Transcriptome-wide association studies [14,20,21,22,23,24,25].
Figure 1. Overview of GWAS of MI workflow and its clinical implications. The GWAS workflow is shown in the gray boxes. The clinical implications of the GWAS results are shown in the white boxes. Genetic data are obtained for individuals with and without an MI phenotype. Genotyping of the genomes of the included individuals is performed. GWAS results are visualized in a Manhattan plot, with the y-axis representing −log10 p-values and the x-axis representing chromosomal positions. The effect sizes of associated SNPs are used for risk prediction with polygenic risk scores, which can be combined with clinical risk scores using non-genetic risk factors. The SNP variants associated with MI can be further analyzed by performing functional research. This can provide insights into biological mechanisms associated with MI and pinpoint potential treatment targets. EQTL, Expression quantitative trait locus; GWAS, Genome-wide association study; MI, Myocardial infarction; PRS, Polygenic risk score; TWAS, Transcriptome-wide association studies [14,20,21,22,23,24,25].
Jcdd 13 00127 g001
Jcdd 13 00127 g002
Figure 2. PRISMA Flowchart of article search for GWAS of MI. Flowchart representing the search for GWAS on MI performed in PubMed and the GWAS Catalog on 1 October 2025. GWAS, Genome-wide association studies; MI, Myocardial infarction.
Figure 2. PRISMA Flowchart of article search for GWAS of MI. Flowchart representing the search for GWAS on MI performed in PubMed and the GWAS Catalog on 1 October 2025. GWAS, Genome-wide association studies; MI, Myocardial infarction.
Jcdd 13 00127 g002
Table 1. Characteristics of GWAS of MI included in the systematic review.
Table 1. Characteristics of GWAS of MI included in the systematic review.
TitlePMIDAuthorJournalYearStudy CohortCases and Controls Definition
A common variant on chromosome 9p21 affects risk of myocardial infarction17478679Helgadottir A. et al.Science20071607 European ancestry cases, 6758 European ancestry controlsCases with MI with age at onset <70 in males and <75 in females. Controls without history of CAD
Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants19198609Kathiresan S. et al.Nat Genet20092967 European ancestry cases, 3075 European ancestry controlsCases with MI with age at onset ≤50 in males and ≤60 in females. Controls without MI matched on sex and age
Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies21239051Reilly MP et al.Lancet20115783 European ancestry cases, 3644 European ancestry controlsCases undergoing cardiac catheterisation who had angiographic CAD and MI (≤55 in males and ≤60 in females). Controls undergoing catheterisation without angiographic CAD and no MI who were >45 years old
SNPs on chromosome 5p15.3 associated with myocardial infarction in Japanese population21107343Aoki A. et al.J Hum Genet2011194 Japanese ancestry cases, 1539 Japanese ancestry controlsCases with MI. Controls without MI and other diseases including asthma, breast cancer, lung cancer, hyperthyroidism, osteoporosis, chronic obstructive pulmonary disease, pollinosis and atopic dermatitis
A genome-wide association study identifies PLCL2 and AP3D1-DOT1L-SF3A2 as new susceptibility loci for myocardial infarction in Japanese24916648Hirokawa M. et al.Eur J Hum Genet20151666 Japanese ancestry cases, 3198 Japanese ancestry controlsCases with MI having a coronary angiography and left ventricular asynergy on echocardiography. Controls without MI who were healthy volunteers and GWAS case samples for other diseases in the BioBank Japan without stable angina, unstable angina, or MI
Genome-Wide Association Study for Incident Myocardial Infarction and Coronary Heart Disease in Prospective Cohort Studies: The CHARGE Consortium26950853Dehghan A. et al.PLoS One20161570 European ancestry cases (at least), 21,618 European ancestry controlsCases with MI (both fatal and non-fatal). Controls without MI and CHD
A genome-wide association study reveals susceptibility loci for myocardial infarction/coronary artery disease in Saudi Arabs26708285Wakil SM et al.Atherosclerosis2016866 Saudi Arab ancestry cases, 371 Saudi Arab ancestry controlsCases with unstable angina, non-ST or ST-elevation MI who underwent cardiac catheterization and were diagnosed through ECG manifestations and changes in biomarkers. Controls without MI and coronary stenosis who underwent surgery for heart valvular diseases
Genome-wide meta-analysis identifies novel susceptibility loci for myocardial infarction33532862Hartiala JA. et al.Eur Heart J202117,505 European ancestry cases, 454,212 European ancestry controlsCases with: (1) Doctor-diagnosed MI; (2) International Classification of Diseases version-10 (ICD10) main and secondary; (3) Self-reported MI. Controls without MI
Uncovering myocardial infarction genetic signatures using GWAS exploration in Saudi and European cohorts38072966Al-Ali AK. et al.Sci Rep20233950 Saudi-Arabian cases, 2324 Saudi-Arabian controlsCases with MI visiting the hospital age 5–66. Controls without MI and coronary stenosis who underwent surgery for heart valvular diseases
Table showing the characteristics of the nine GWAS of MI identifying genome-wide significant SNPs. Cases and controls definitions are reported as in the studies. GWAS, Genome-wide association studies; MI, Myocardial infarction [5,25,30,31,32,33,34,35,36].
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Thierry, I.P.; Jabbari, R.; Engstrøm, T.; Tfelt-Hansen, J.; Glinge, C. Genome-Wide Association Studies of Myocardial Infarction: A Systematic Literature Review. J. Cardiovasc. Dev. Dis. 2026, 13, 127. https://doi.org/10.3390/jcdd13030127

AMA Style

Thierry IP, Jabbari R, Engstrøm T, Tfelt-Hansen J, Glinge C. Genome-Wide Association Studies of Myocardial Infarction: A Systematic Literature Review. Journal of Cardiovascular Development and Disease. 2026; 13(3):127. https://doi.org/10.3390/jcdd13030127

Chicago/Turabian Style

Thierry, Isabelle P., Reza Jabbari, Thomas Engstrøm, Jacob Tfelt-Hansen, and Charlotte Glinge. 2026. "Genome-Wide Association Studies of Myocardial Infarction: A Systematic Literature Review" Journal of Cardiovascular Development and Disease 13, no. 3: 127. https://doi.org/10.3390/jcdd13030127

APA Style

Thierry, I. P., Jabbari, R., Engstrøm, T., Tfelt-Hansen, J., & Glinge, C. (2026). Genome-Wide Association Studies of Myocardial Infarction: A Systematic Literature Review. Journal of Cardiovascular Development and Disease, 13(3), 127. https://doi.org/10.3390/jcdd13030127

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop